Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Heteroaryl compounds and their use

a technology of heteroaryl compounds and compounds, applied in the field of heteroaryl compounds, can solve problems such as diarrhea, peripheral nerve damage, side effects,

Active Publication Date: 2019-11-07
MINORYX THERAPEUTICS
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes a new technology and its advantages. The text explains that the technology has certain elements and combinations that make it possible to achieve certain technical effects. The text is not meant to restrict the use of the technology in any way. The technical effects of the patent text can be presumed to include improved performance, efficiency, or other benefits in the use of the technology.

Problems solved by technology

While ERT may be effective in reducing and reversing the clinical symptoms of the disease, it is very costly.
While SRT may be effective for some patients, it is associated with side effects, including weight loss, diarrhea, tremors, and peripheral nerve damage.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Heteroaryl compounds and their use
  • Heteroaryl compounds and their use
  • Heteroaryl compounds and their use

Examples

Experimental program
Comparison scheme
Effect test

example 1

6-((Methyl(phenyl)amino)methyl)-N2-(p-tolyl)-1,3,5-triazine-2,4-diamine

[0322]

[0323]Yield: 9%.

[0324]HPLC-MS [M+H]+: 321; Rt=2.72 min (Method C).

[0325]1H NMR (400 MHz, CDCl3) δ: 7.28 (s, 2H), 7.15 (ddd, J=7.3, 5.9, 2.3 Hz, 2H), 7.00 (d, J=7.4 Hz, 2H), 6.84 (s, 1H), 6.71 (dd, J=8.8, 0.9 Hz, 2H), 6.65 (td, J=7.3, 1.0 Hz, 1H), 5.04 (s, 2H), 4.26 (s, 2H), 3.07 (s, 3H), 2.24 (s, 3H).

example 2

N2-(4-Methoxyphenyl)-6-((methyl(phenyl)amino)methyl)-1,3,5-triazine-2,4-diamine

[0326]

[0327]Yield: 6%.

[0328]HPLC-MS [M+H]+: 337; Rt=2.43 min (Method C).

[0329]1H NMR (400 MHz, CDCl3) δ: 7.24 (d, J=20.0 Hz, 2H), 7.18-7.13 (m, 2H), 6.79 (s, 1H), 6.75 (s, 2H), 6.72-6.68 (m, 2H), 6.67-6.62 (m, 1H), 5.05 (s, 2H), 4.25 (s, 2H), 3.72 (s, 3H), 3.05 (s, 3H).

example 3

N2-β-Methoxyphenyl)-6-((methyl(phenyl)amino)methyl)-1,3,5-triazine-2,4-diamine

[0330]

[0331]Yield: 21%.

[0332]HPLC-MS [M+H]+: 337; Rt=2.65 min (Method C).

[0333]1H NMR (400 MHz, CDCl3) δ: 7.19 (d, J=2.1 Hz, 1H), 7.17-7.13 (m, 2H), 7.10 (t, J=8.5 Hz, 1H), 6.97 (s, 1H), 6.93 (dd, J=8.2, 1.4 Hz, 1H), 6.69 (dt, J=3.5, 1.8 Hz, 2H), 6.64 (tt, J=5.0, 2.5 Hz, 1H), 6.57-6.51 (m, 1H), 5.16 (s, 2H), 4.26 (s, 2H), 3.70 (s, 3H), 3.07 (s, 3H).

General Procedure III

[0334]

[0335]To a stirred solution of the appropriate biguanide hydrochloride salt (ex: p-tolylbiguanide) (1.0 eq) in methanol (2.4 mL / mmol) was added sodium methoxide (1.0 eq, 25 wt % in methanol) at room temperature and it was stirred for 30 min. The appropriate ester was added to the reaction mixture (ex: ethyl N-benzyl-N-methylglycinate) (1.2 eq) and heated to 70° C. for 18 h. After reaction completion, the reaction mixture was poured into cold water and the organic product was extracted with ethyl acetate. Organic extracts were dried ove...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
Login to View More

Abstract

The application is directed to compounds of formula (I): and their salts and solvates, wherein R1, R2, R3, A1, A2, A3, and n are as set forth in the specification, as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and / or prevention of a lysosomal storage disease, such as Gaucher's, and other diseases or disorders that are synucleinopathies.

Description

CROSS-REFERENCE TO RELATED APPLICATION[0001]This application claims priority to European Application No. EP16382672.0, filed on Dec. 29, 2016, the entirety of which is incorporated by reference herein.FIELD OF THE DISCLOSURE[0002]The present disclosure is related to heteroaryl compounds, and especially pyridyl, pyrimidinyl, and triazinyl compounds, new processes for their preparation, and the use of the heteroaryl compounds in the treatment and / or prevention of lysosomal storage disorders in a patient, such as Gaucher's disease. The present disclosure is also related to the use of the heteroaryl compounds described herein in the treatment and / or prevention of other medical disorders in a patient, such as, for example, Parkinson's disease, Lewy body disease, dementia, multiple system atrophy, epilepsy, bipolar disorder, schizophrenia, an anxiety disorder, major depression, polycyctic kidney disease, type 2 diabetes, open angle glaucoma, multiple sclerosis, or multiple myeloma.BACKGRO...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07D401/06C07D239/49C07D401/12C07D405/12C07D403/06C07D251/18A61P43/00
CPCC07D401/06C07D239/49C07D401/12A61P43/00C07D403/06C07D251/18C07D405/12C07D239/48C07D251/48C07D213/36A61P25/00A61P25/16A61P25/28A61K31/44A61K31/53C07D213/74A61K31/505A61K31/506
Inventor GARCÍA COLLAZO, ANA MARIABARRIL ALONSO, XAVIERCUBERO JORDÀ, ELENAREVÉS VILAPLANA, MARCROBERTS, RICHARD SPURRING
Owner MINORYX THERAPEUTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com